Figure 3From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin Change in WOMAC Functional Scores/100 by Visit and Study Group. Statistical significant change in Functional Scores was only observed in the UP446 treatment groups, UP446 250 mgs/day and UP446 500 mgs/day.Back to article page